Stock ONC ONCIMMUNE HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Oncimmune Holdings plc

Equities

ONC

GB00BYQ94H38

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:27 2024-05-21 am EDT 		5-day change 1st Jan Change
25.6 GBX +2.81% Intraday chart for Oncimmune Holdings plc +5.35% +1.59%
May. 21 Earnings Flash (ONC.L) ONCIMMUNE HOLDINGS Posts Fiscal H1 Revenue GBP1.2M MT
Feb. 29 Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024 CI

Business Summary

Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.

Number of employees: 52

Sales per Business

GBP in Million2022Weight2023Weight Delta
ImmunoINSIGHTS
100.0 %
2 60.8 % 1 100.0 % -37.47%

Sales per region

GBP in Million2022Weight2023Weight Delta
Rest of the World
93.1 %
1 21.4 % 1 93.1 % +65.64%
Europe
6.9 %
1 19.8 % 0 6.9 % -86.67%

Managers

Managers TitleAgeSince
Martin Gouldstone CEO
 Chief Executive Officer 57 23-07-31
Martin Hudson DFI
 Director of Finance/CFO - 23-09-03
James R. Jett CTO
 Chief Tech/Sci/R&D Officer - 15-10-31
Tariq Sethi CTO
 Chief Tech/Sci/R&D Officer - 19-09-30
Ron Kirschner COO
 Chief Operating Officer - 20-04-19
Cléa Rosenfeld IRC
 Investor Relations Contact - 19-06-30
Matthew Luttrell PRN
 Corporate Officer/Principal - 19-09-30
Cameron Barnard PRN
 Corporate Officer/Principal - 21-07-31

Members of the board

Members of the board TitleAgeSince
John Goold BRD
 Director/Board Member 52 23-01-12
Timothy Bunting BRD
 Director/Board Member 61 15-10-08
Ron Kirschner COO
 Chief Operating Officer - 20-04-19
Martin Gouldstone CEO
 Chief Executive Officer 57 23-07-31
Sally Christina Waterman BRD
 Director/Board Member - 23-10-11
Alistair Macdonald CHM
 Chairman 54 22-07-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,142,147 52,785,507 ( 71.20 %) 0 71.20 %

Shareholders

NameEquities%Valuation
Balderton Capital (UK) LLP
9.189 %
6,813,196 9.189 % 2 M p
Richard Sharp
6.597 %
4,891,444 6.597 % 1 M p
Timothy Bunting
6.551 %
4,856,717 6.551 % 1 M p
Gene Group Holdings Ltd.
4.445 %
3,295,659 4.445 % 953 269 p
Hargreaves Lansdown Asset Management Ltd.
4.232 %
3,137,967 4.232 % 907 657 p
Chelverton Asset Management Ltd.
4.056 %
3,007,500 4.056 % 869 919 p
SpreadEx Ltd.
2.486 %
1,843,032 2.486 % 533 097 p
Unicorn Asset Management Ltd.
1.565 %
1,160,000 1.565 % 335 530 p
John Goold
1.551 %
1,150,000 1.551 % 332 638 p
Maven Capital Partners UK LLP
0.4869 %
360,985 0.4869 % 104 415 p

Company contact information

Oncimmune Holdings Plc

D6 Building 1 Thane Road

NG90 6BH, Nottinghamshire

+

http://www.oncimmune.co.uk
address Oncimmune Holdings plc(ONC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per Business

Sales per region

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
ONCIMMUNE HOLDINGS PLC Stock Oncimmune Holdings plc
+1.59% 24.12M
MERCK KGAA Stock Merck KGaA
+14.99% 78.22B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+8.44% 8.84B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-12.05% 5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+53.66% 4.82B
YUHAN CORPORATION Stock Yuhan Corporation
+11.63% 4.2B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-23.67% 2.28B
INDIVIOR PLC Stock Indivior PLC
+12.07% 2.28B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-32.35% 2.12B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+21.04% 2.2B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ONC Stock
  4. Company Oncimmune Holdings plc
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW